Biotie regains rights to develop PDE10 inhibitors for CNS disorders

19-Oct-2010 - Finland

Biotie announced that it will regain rights to compounds relating to PDE10 inhibition for the treatment of CNS disorders, including schizophrenia. The compounds were the subject of a four-year collaboration with Wyeth (which was acquired by Pfizer in 2009) which started in 2006 and which yielded several promising PDE10 inhibitors that have demonstrated activity in pre-clinical models of schizophrenia.

Timo Veromaa, Chief Executive Officer of Biotie commented, "We are excited about PDE10 as a novel target for the treatment of schizophrenia and other disorders of the central nervous system. We have had a succesful research collaboration with Wyeth, and then Pfizer, and together we have generated supportive data for this class. We are now in a position to pursue novel clinical candidates going forward."

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance